Feldan News

Using the Feldan Shuttle technology, our team and collaborators have successfully demonstrated for the first time, the feasibility of base editing in non-human primate lungs. This study provides in vivo …

Québec City, Canada, October 3, 2023 - Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, is …

Congratulations to Xiaoming Liu’s team for the publication of the article: Genome Editing in Ferret Airway Epithelia Mediated by CRISPR/nucleases Delivered with Amphiphilic Shuttle Peptides The team used our delivery …

Feldan is proud to announce that it will receive advisory services and up to $563,000 in funding from the National Research Council Canada, Industrial Research Assistance Program (NRC- IRAP) for …

Feldan is awarded an Applied Research and Development grant via the College and Community Innovation (CCI) program, for a total amount of $450,000. This funding will help develop Feldan Shuttle …

Québec City, Canada, June 13, 2023 – Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing …

MONTREAL, April 18, 2023 – CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat …

Feldan Therapeutics is pleased to share the promising results of FLD103 to treat basal cell carcinoma. A poster presented at the WCH23 Dermatology Conference last January (Intralesional Treatment of Basal …

Quebec City, Canada, January 18, 2022 - Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the …

Read more on pages 54 to 57: BIOTECanada Insights sping 2021 …